NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for previously untreated adults with multiple myeloma who are eligible for an autologous stem cell transplant (ASCT). Under the recommendation, patients can receive D-VRd as induction and consolidation treatment around their transplant, followed by daratumumab plus lenalidomide maintenance. The guidance also […]
The post NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma appeared first on Pharmafile.